Iron Metabolism Disorders Withdrawn Phase 2 Trials for Deferasirox (DB01609)

IndicationStatusPhase
DBCOND0040533 (Iron Metabolism Disorders)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01927913Treatment of Iron Overload Requiring Chelation TherapyTreatment